# OnCo record nct06516289 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06516289/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06516289", "NCT06516289" ;
  schema:name "Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab"@en ;
  schema:description "This study tests a PARP inhibitor; the registry reports that it is recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06516289/> ;
  schema:dateModified "2026-10-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06516289> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  schema:startDate "2024-09-30" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/hrs-1167/> .